Silver diamine fluoride in the medical management of oral disease

2018 ◽  
Vol 63 (5) ◽  
pp. 327-329
2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Beril Mendi ◽  
Ece Eden

2021 ◽  
pp. 1-13
Author(s):  
Mohammed Zameer ◽  
◽  
Sameen Badiujjama Birajdar ◽  
Syed Nahid Basheer ◽  
Syed Wali Peeran ◽  
...  

Dental caries is the most prevalent oral disease that continues to affect almost every country in the world. The contemporary management of dental caries focuses on non-restorative, non-invasive, and micro-invasive treatment approaches that arrest or reverse the caries process at a lesion level and reduce the loss of sound tooth structure. One of these approaches is the employment of caries arresting agents that possess antibacterial and remineralizing properties. Silver diamine fluoride (SDF) has drawn significant attention as an efficient caries arresting agent in children and adults. The major limitation with the use of SDF is the dark black staining of the carious tissue that compromises the esthetics. Silver ions are known for their antimicrobial effects, and silver nanoparticles (AgNPs) have the added advantage that it increases the surface area for exposure to the microbes. Literature reports that AgNPs have antimicrobial potential against predominant cariogenic flora. It has led to the development of nanosilver fluoride (NSF), a new colloid based on AgNPs, chitosan, and fluoride. It has shown to overcome the clinical limitations of SDF as it does not cause carious lesion staining. However, the current scientific literature lacks a comprehensive review of the benefits of using NSF for caries prevention and arrest. Thus, the purpose of this paper was to review the studies and clinical trials on NSF as a caries arresting agent, including antibacterial actions and modulation of the demineralization-remineralization balance.


Author(s):  
Amy Lustig ◽  
Cesar Ruiz

The purpose of this article is to present a general overview of the features of drug-induced movement disorders (DIMDs) comprised by Parkinsonism and extrapyramidal symptoms. Speech-language pathologists (SLPs) who work with patients presenting with these issues must have a broad understanding of the underlying disease process. This article will provide a brief introduction to the neuropathophysiology of DIMDs, a discussion of the associated symptomatology, the pharmacology implicated in causing DIMDs, and the medical management approaches currently in use.


2006 ◽  
Vol 175 (4S) ◽  
pp. 464-465
Author(s):  
Michael J. Naslund ◽  
Muta M. Issa ◽  
Libby Black ◽  
Michael Eaddy ◽  
Manan Shah

2006 ◽  
Vol 175 (4S) ◽  
pp. 3-3 ◽  
Author(s):  
John T. Wei ◽  
James Nuckolls ◽  
Martin Miner ◽  
Raymond C. Rosen ◽  
Claus G. Roehrborn
Keyword(s):  

2004 ◽  
Vol 171 (4S) ◽  
pp. 42-43 ◽  
Author(s):  
Yair Latan ◽  
David M. Wilhelm ◽  
David A. Duchene ◽  
Margaret S. Pearle

Sign in / Sign up

Export Citation Format

Share Document